HSP90 Heat-Shock Proteins, antagonists & inhibitors
- HSP90 Heat-Shock Proteins, antagonists & inhibitors
- Accession Number
Drug Drug Description Tanespimycin Investigated for use/treatment in leukemia (myeloid) and solid tumors. Retaspimycin Investigated for use/treatment in gastric cancer, lung cancer, and multiple myeloma. Onalespib Investigated for use/treatment in cancer/tumors (unspecified). AUY922 AUY922 has been used in trials studying the treatment of Lymphoma, Breast Cancer, Metastatic Disease, Advanced Solid Tumors, and Hematologic Neoplasms, among others. Ganetespib Ganetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome. BIIB021 BIIB021 has been investigated for the treatment of Tumors and Lymphoma. XL-888 XL888 has been used in trials studying the treatment of Cancer and Melanoma. IPI-493 IPI-493 has been used in trials studying the treatment of Advanced Malignancies. SNX-2112 SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor.
- Drugs & Drug Targets
Drug Target Type Tanespimycin Heat shock protein HSP 90-alpha target Tanespimycin Heat shock protein HSP 90-beta target Tanespimycin Serum albumin carrier